Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/000884

International filing date:

12 January 2005 (12.01.2005)

Document type:

Certified copy of priority document

Document details:

Country/Office: US

Number:

60/535,908

Filing date:

12 January 2004 (12.01.2004)

Date of receipt at the International Bureau: 21 February 2005 (21.02.2005)


Remark:

Priority document submitted or transmitted to the International Bureau in

compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



THE ASSESSED WELLOW THE SECTION OF T

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

February 07, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/535,908

FILING DATE: January 12, 2004 RELATED PCT APPLICATION NUMBER: PCT/US05/00884

Certified by

Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office

NO. 751

2:31PM

Provisional Application Cover Sheet

Address to: Washington, DC 20231

Express Mail #: BR519392846US

This is a request for filing a PROVISIONAL APPLICATION under 37 C.F.R. § 1.53(b)(2).

D	ocket Number: Q3399	Type this t	e plus sign (+) insido	+
inventor(s)/App	liosut(s)			
Last Name	First Name	Middle Inittel	Residence (City and eit Poreign Country)	her Stats or
Siegól Winey	Steven Karen		Berwyn, PA Philadelphia, PA	
Title of the Inve	ntion (280 Characters Maximus)		
A Long-Term Biodegrad	able Permulation for Risperidors	and 9-oh-ris	peridone	
Correspondence	Address			
University of Pennsylvan			•	
Center For Technology T	Yansfer			
3160 Chestnut Street	!			1
Suite 200	i			,
·				
City: Philadelphia		ode: 19104 -	6283 Country: US	
	cation Parts (check all that apply	2		
[X] Specification Number	per of pages 16 [] Small	Builty Statem	eni	
		·		
[] Drawing(s) Numb	ber of sheets [] Other	specury)		
Method of Payr	nont (check one)	1.00	a. A Provisional	
[] Our Check No.	is enclosed to cover the Provis	our und id	Filing Fee	
duplicate copy of this sh	ect is enclosed.		Amount (\$)	\$ 80.00
	is hereby authorized to charge fi	Hino fore and		
[X] The Communicationer	-2489. A diplicate copy of this	theat is enclose	od.	į.
Deposit Account No. 13	· Mas. A adhinem ropy or time i			l l
[] Payment by credit ca	ord. Porm PIO-2028 is attached.	,		

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

No
[] Yes, the name of the U.S. Government agency and the Government contract number are:

Respectfully submitted

Typed or Printed Name: Steven Sieg

[] Additional inventors are being named on separately numbered sheets attached hereto.

PROVISIONAL APPLICATION FILING ONLY

PROVISIONAL APPLICATION SUBMISSION TO USPTO - CONTENTS PAGE

Penn Docket Number:

Q3399

First-named Inventor:

Siegel

Submission Date

1/12/04

Prepared by

Matt Thomas

CONTENTS LISTED IN ORDER:

Page Nos.	Descriptor
1 2-3 4-16	This Page Disclosure Summary Risperidone Figures and Charts

Total Number of Pages : 16

Siegel, S. J. et. al. Risperidone and 9-OH Risperidone

Brief Summary

We have devised a long-term delivery formulation for the antipsychotic agent risperidone and its active metabolite 9-oh-Risperidone. Risperidone is currently in use for the treatment schizophrenia, bipolar disorder, Alzheimer's Disease, psychotic depression, and other mental conditions that cause confusion, disorganization and psychosis. The current formulation would allow for incorporation of both risperidone and 9-oh-risperidone into multiple delivery platforms including:

- 1. Surgically implantable formulation: this method would be best suited for the treatment of chronic conditions listed above.
- Incorporation into nanoparticles for stealth long-term delivery through the GI tract.
 As PLGA loaded nanoparticles are delivered across the intestinal mucosa, active drug would evade first pass metabolism. Additionally, this method could deliver antipsychotic activity for one-week interval.
- 3. The use of 9-oh-risperdidone is included since this molecule has a hydroxyl functional group that allows for ester bond formation, and creation of pro-drug polymers that will deliver improved controlled release as compared to physical mixtures.

Stage of development

We have tested multiple compounds in PLGA delivery systems in vitro. These studies indicate that every drug results in a different pattern of release. Risperidone and 9-oh risperidone result in a highly stable drug-polymer matrix with kinetics that approach steady state over the delivery interval, even with a polymer (50:50 PLGA) that traditionally yields a high degree of drug dumping after an initial lag. Additionally, we are able to make nanoparticles with PLGA and incorporate drugs into these particles for oral delivery systems.

Applications/Commercial use

The commercial application of this technology is related to treatment of schizophrenia, bipolar disorder, Alzheimer's Disease, psychotic depression, and other mental conditions that cause confusion, disorganization and psychosis.

Closest know similar technology


Current formulations of risperidone include daily oral formulations and biweekly PLGA based microspheres (Risperidone Consta). There are no pro-drug polymers utilizing 9-oh risperidone in use, or that we are aware of in development.


Differences / advantages


The major advantages to a long-term polymer based delivery system for this drug include:


Steady state delivery over weeks to months, avoiding peaks and troughs from oral dosing

- Lower dosing through avoidance of first pass metabolism resulting in less systemic toxicity.
- Greater ease of administration with resulting in improved adherence as compared to current oral medications.
- Long term implants t offer a degree of treatment adherence (annual) and resulting improvement that is not currently available in any psychiatric medication.












	•	ä	8	8	å	Pos Control	ABSORBANCE	NC.	Pos Control Correction Coefficient P1C	cefficient P1		220	ည္က	
ABSORBANCE	Neg Corne	ABS	AGS	ABS	ABS		G ay	•	ABS	ACC.			2	
, ec	200	0.004		0.004	0.00	0.382		-						
			_	90.0	0	0.427		7		1100	600 0	9000	40.012	
	9000		-	9.009	0.002	0.47		*		2000	0000	0.017	0.003	
	4 0 005			0.02	900.0	0.459				9000	0.00	0.019	0.001	
			_	0.025	0.00	0.462		.		600	0.016	0 031	9000	
•	1000		_	400.0	6000	0.459		= :		6	0.026	0.046	0.013	
				0.044	0.011	254.0		Ξ :		7000	2000	900	0.055	
	600	_		0.052	0.057	0.458		9		7000	0000	9	0.014	
·				9500	0.014	0.456		5	_	9000	2000	690	9100	
	2 2			0.063	0.017	0.457		≂ '		100.0	600	900	9 6	
	100.00			0.066	6100	0.456		ຂ		0.000	0.03	2000		
				720	200	0.466		22		0.00	\$ 6000 6000	200		
				200	200	0.451		8	_	0.00	250.0	900	20.0	
						0.440		ន		0.00	0.055	0.088	0.030	
				0.00	0.023	777		H	01	800. Q	0.057	0.063	60.0	
			_	0.081	0.026	0.40		35		900.0	0.063	0.103	0.036	
		_		60.0	000	6.0		75		0.009	0.060	0.101	0.033	
	37 0.009			=	0.042	0.453				0.003	0.076	0.118	0.048	
		11 0.073	_	0.115	0.045	0.453		, -		9009	0.084	0.133	950.0	
		9700	_	0.128	0.051	0.451		•	•	9000	0.092	0.142	090'0	
			_	0.136	0.054	0.45		₹ .	•	9	100	0 147	0.063	
	60.0			6 143	0.059	0.452		4	46	7000	3	5		
			2	}		0.456								
						;			CONCENTRATION	•	51	22		Avg (P1, P2, P3)
CONCENTRATION	Neo Control	٦	2	£		Pos Control	1		i	•	Conc		క్ర	Š
Concentration		S	S	S	J	Conc	Avg (P1, P2, P3)		â	, c	2			
ŝ	, nonmus 343	13 0 00051095		50109	0,0003893	0.015839416	0.000470397							
						0.017664234	0.000429846			٠.	4 COUNTY OF O COURSE	2770000	40000	.2 70343F-06
	0.000.00					0.019407948	0.000565018			4 1	-1.622005-03	0.000	7	0.000754258
		•				0.018961882	0.000875912			- 1	0.000757000		2000	0.000754258
	9					0.019083536	0.000997567			on ,	0.000/34238		0,000,00	275 0000
	0,00026					0.018961882	0.001186807			=	0.00039730		255000.0	2000000
	11 0.0003081		-			0.010250124	0.001416599			7	0.001403082		0.000976	2071241000
	14 6.48824E-05					0.0000000	0.002214112			16	0.001443533	•	6/5700'0	0.0021300.0
	16 0.000267					0.01932133	0.001686942			1 8	0.001524736			0.001686942
	18 0.000346743		_	_	_	0.010000000	0.00100317			2	0.001727494			0.001862666
	21 0.000308191		_	_		0.016860779	0.001903217			23	0.001930251	0.003025		0.002024872
	23 0.000389294		_		0.0011192	0.018840227	0.002024872			25	0.001727494	0.002944	0.000795	0.001822114
	Ĭ	102 0.00213301	_	0,0033496 0	0.0012003	0.019245742	0.00222/629			5	0.002457421		0.001444	0.002497972
	•		_	0.0033901 0	0.0012409	0.01863747	0.002295215			8	0.002579075	0.003917	0.001565	0.002687213
				0.0036334 0	0.0012814	0.018556367	0.002403352			3 8	0.002660178			0.002781833
				0.0036334 0	0.0014031	0.018515815	0.002457421			4 4	0.007003487			0,003079211
				0.0042822 0	0.0015653	0.018595918	0.002835902			3 6	0.002281833			0.002971073
				_	0.0020519	0,019205191	0.003336037			5 6	0.002730657			0.003619897
	30 0.000154358			_	0.0021735	0.016718573	0.003496243			3 (0.00000000			0.004038929
		c			0.0024169	0.01863747	0.003836172			? ;	0.003733069		_	0.00432279
				-	0.0025385	0.018596918	0,004079481			9	0.004073401			0.004539065
	44 0.000713700				0.0027413	0.018678021	0.004376659			46	0.00440303			0.000


_	Total Drug Total Drug Total Orug Total Orug	0 0.255474453 0.255474 0.194647 0.235198702	2 0.214922952 0.255474 0.174371 0.214922952	4 -0.0081103 0.072993 -0.06894 -0.001351717	7 0.377128954 0.519059 0.235199 0.377128954	0.559611 0.194647 0.	0.80292 0.296026 0	1.107056 0.437956 0.	1.188159 1.289538	0.458232	1,431468 0,498783	.512571 0.559611	1,472019 0,397405	796431	1.956637 0.782644	1.978913 0.863747 1.	0.904298	37 1,390916464 2,222222 0,843471 1,485536632	39 1,715328467 2,56691 1,147607 1,809948635	43 1.877534469 2.871046 1.309813 2.01946472	3.053528 1.390916 2		46 2.201940472 3.154907 1.451744 2.20352345
500 mL	Corrected Day																						
Avg (P1, P2 P3)	Total Drug	0.235198702	0.214922952	0.282508786	0.437956204	0.498763455	0.593403623	0.70829954	1,107055961	0.843471208	0.951608543	1.012435793	1,113814544	1,147607461	1,201676129	1,228710462	1,417950798	1,668018383	1 749121384	1 018085060	E10000000	2.039/404/	2,188429305
Pos Control A		8	8.832116788	9 703974047	9.480940795	9,541768045	9.480940795	9.379562044	9.460565045	9,420113544		9,420113544	9.622871046	9.318734793	9.278183293	9.257907543	9.298459043		0	0.310734703	n ('n	9.339010543
2	Total Doug	0.1946472	0.1743715	0.214923	0.296026	0.3163017	0.3568532	0.3974047	1,3300892	0.458232	0.5190592			0.620438				1 025953	4 0867807		-	1,269262	1,3706407
P2	Total Drug	0 2554745	_	, .	0.5798865	0 5812652	0.863747	_	1,2287105	1,3098135	1,4517437		1,674777		1.8167072			۱ _	٠,	, c	•	2,9318735	7.038037
	Ord Para	0.25547445	0.21402705		04179562	' c	, 0	_	_	0		0.96512571	1.06650446	1,12733171	1 14750746	1.16788321		-	•		_	1.91808597	2.12084347
۵							. ~	~	5	G	8	8	8	8	8	3	5	į	į	5	ž	ĕ	Ž
Mon Control	Total Date	C27171451	0.154005702	0.052746951	0.072002701	0.17819951	0.154095702	0.0324412	0.133819951	0.174371452	0.154095702	0 1946472	0.791970A	0 373073804	V.2027F. 0.	20 3933495	1123276561	A 156851704	1111111	0.311120334	17.0377726354	0.356853204	0.377128954

500 mL Corrected Day









			Any (P1, P2, P3) (000991
S	0.468 0.474 0.474 0.474 0.474 0.477 0.477 0.477 0.447 0.447 0.469	5	Cone Cone Cone Awy Pil. P. (2000) 0,001243 0,0000716 0,0101247 0,0000931 0,0001243 0,0000931 0,0001243 0,0000931 0,0001243 0,0000931 0,0001243 0,0000931 0,0001243 0,0000931 0,0001243 0,00001243 0,0001243 0,0001243 0,0001243 0,0001243 0,0001243 0,0001243 0,
s	0.005 0.005 0.001 0.011 0.005 0.005 0.005 0.115 0.136 0.136 0.136 0.156 0.156	_	Corr C 0.000716 0.000716 0.000716 0.000716 0.0000716 0.000072 0.000154 0.000154 0.000175 0.000175 0.000175 0.000175 0.000175 0.000175 0.000175 0.000175 0.000175 0.000175 0.000175 0.000175 0.000175 0.000175 0.000175 0.000175
	0,014 0,011 0,023 0,032 0,046 0,111 0,131 0,147 0,143 0,143 0,143	_	
υ	0.002 0.004 0.009 0.009 0.019 0.102 0.102 0.165 0.165 0.165 0.163 0.163 0.173 0.173 0.173	•	Conc.
Day ABS AB		46 0.01 CONCENT Neg Contr P1	Conc 0 0,000716 2 0,00048 7 0,00048 11 0,000678 11 0,000678 14 0,000678 16 0,000678 17 0,000678 18 0,00078 21 0,00078 22 0,00078 23 0,00078 24 0,00078 27 0,00078 28 0,00078 29 0,00078 20 0,00078 21 0,00078 22 0,00078 23 0,00078 24 0,00078 25 0,00078 26 0,00078 27 0,00078 28 0,00078 29 0,00078 20 0,00078 21 0,00078 22 0,00078 23 0,00078 24 0,00078 25 0,00078 26 0,00078 27 0,00078 28 0,00078 29 0,00078 20 0,0007
ABSOKE Day	2222(4)		6 A
¥30			
20% KISP 63.13		į	
%0Z		i	Avg (P1, P2, P3) 0,000690677 0,001004621 0,001055416 0,001255777 0,001252772 0,001252772 0,001252772 0,001252772 0,001252772 0,001252772 0,001252772 0,001252772 0,001252772 0,00125272 0,001252772 0,00125272 0,00125272 0,00125272 0,00125272 0,00125272 0,00125272 0,00125272 0,00125272 0,00125272 0,00125272 0,00125272 0,00125272 0,00125272 0,00125272 0,00125272
Pos Control	0.456 0.474 0.474 0.474 0.472 0.472 0.473 0.471 0.471 0.471 0.471 0.445 0.445 0.445 0.445 0.445	0.481	Control Ava 0.018346896 0.018761302 0.018772396 0.018572396 0.018572396 0.018572396 0.018572396 0.018572396 0.018572396 0.018572396 0.018572396 0.018572396 0.018572396 0.018572396 0.018572396 0.018572396 0.018572396 0.018572396 0.018572396 0.017555756 0.017555756 0.017555756 0.017555756 0.017555756 0.017555756 0.017555756 0.017555756 0.017555756 0.017555756 0.017555756 0.017555756 0.017555756 0.017555756 0.017555756
	0 0005 0003 00005	0.207	PG C007158 C007158 C011302 C011302 C011302 C011302 C01302 C01302 C01302 C0030315 C00603 C0
	ABS 0.0014 0.0011 0.0011 0.002 0.005 0.108 0.141 0.147 0.144 0.144 0.145 0.145	0.208	P3 (COO) 18
8	ABS 0.002 0.004 0.003 0.019 0.019 0.015 0.156 0.165 0.165 0.17 0.17		P2 (See 1979) P2 (See 1979) P3 (See 1979) P3 (See 1979) P4 (See 1979) P4 (See 1979) P5 (See 1979)
٤.	ABS 0 0 0 0.001 0.005 0.005 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001	0000	115793 0 778119 0 778119 0 227426 0 227426 0 227426 0 245246 0 715793 0 715793 0 715793 0 755466 0 756469 0 756
Neg Control	4444		
	0047911111111111111111111111111111111111	3.4.8	CONCENTRATION Day 2 4 4 4 4 5 23 23 23 23 23 23 23 23 23 23 23 23 23
ABSORBANCE	,		Pay May May May May May May May May May M

Control Bootiling Confedent D1C D2C D3C	27.	0.00419 0.00619	-0.00081 0.00919	-0.00181 0.01119	0.00919 0.02319	0.01919 0.03219	0.04819	914 0.00181 0.07119 0.07519 0.06719	16 -0.00419 0.10819 0.11419 0.09719	18 -0.00419 0.13219 0.11519 0.11919	•	-0.00419 0.16919 0.14419	0.02181 0.17019 0.14819	-0.00219 0.19419 0.16419	-0.00019 0.19719 0.16819	-0.00119 0.19919 0.17219	-0.00219 0.20519 0.18419	37 -0,00019 0,20419 0,16319 0,18919	39 -0.00319 0.20819 0.18819 0.19219	43 -0.00419 0.20919 0.19419 0.19619	021319 020119	46 40.00419 0.21519 0.20819 0.20119	P2C P3C	Conc Conc Conc	0 0.000873644 0.000349 0.000949 0.000923875	2 0.000685277 0.001062 0.000723 0.000823413	_	_	_	0.002531 0.002155	0.003548 0.003247	0.004791667 0.005018 0.004377	0.005695826 0.005055 0.005206	0.006713005 0.005771 0.006148	0.007089738 0.006148 0.00596	0.007127411 0.006299 0.006751	0.006901 0.007504	0,00814459 0,007052 0,007542	0.008219937 0.007203 0.007693	0.008445976 0.007655 0.007681	0.008408303 0.007617 0.007843	0.008558996 0.007806 0.007956	0.008032 0.008107	0.008295 0.008182	46 0.008822709 0.008559 0.008295 0.008558996	
Corrected for Negative and Positive Control	(Pa																						CONCENTRATION	Dav																						
	Oay . neg concer P1 contect P2 contect P3 contect Pos contected	-0.002 0	0.015	900	0.014 0.028	0.021 0.034 0.024	0.039 0.047 0.037	0003 0077 0.069	0.104 0.11 0.093	0 128 0 111 0 115	0 0000 0150 0150 0170	2000 0000 0000	0.03 0.193 0.14 0.183	20.23 0.192 0.152 0.178	0.027 0.197 0.168 0.181	0.02 0.137 0.134 0.038 0.131 0.184	0.054 0.203 0.182 0.188	0.204 0.183 0.189	000 000 0185	0.00 0.00 0.19	0,000 0,196 0,196	0211 0204 0197	CONCENTIVE Contr. P.1 P.2 P.3 Pos Control	Cont	0 000016 000064 0000716 0000716 0018347	2 0.000763 0.000004 0.001281 0.000042 0.018799 0.001042	2 0.000 C. 0.000 C. 0.00135	7 0.000904 0.001243 0.001771 0.001319 0.018761 0.001444	9 0.000791 0.001507 0.001997 0.00162 0.018848 0.001708	0.000753 0.002185 0.002486 0.00211	003466 0,003617 0,003315 0,018648 0		005539	0.000753 0.005631	23 0,000678 0,006932 0,00599 0,005802 0,018422 0,005241	25 0,001582 0,007949 0,00712 0,007572 0,019402 0,007547	28 0,001733 0,007949 0,006819 0,007422 0,018498 0,007397	30 0.001733 0.008137 0.007045 0.007535 0.018573 0.007572	32 0.001771 0.008175 0.007158 0.007648 0.018535 0.00765	35 0,003127 0,008363 0,007572 0,007798 0,018498 0,007911	37 0.000377 0.008401 0.00761 0.007836 0.018573 0.007949	39 0,000339 0,008439 0,007685 0,007836 0,01846 0,007987	43 0.000339 0.008439 0.007874 0.007949 0.018422 0.008087	44 0.000377 0.008665 0.008213 0.0081 0.018498 0.008326	0.000339 0.008665 0.008401 0.008137	

```
Do mi. Total Drug Total Drug Total Drug Total Drug Total Drug Post Cortr Ang (P1.) Fin milligrar orrected Neg Cortr P1

0.0,35766 0,530223 0,537686 0,537686 0,53239 0,0,53768 0,0,53239 0,0,53768 0,0,53269 0,0,53209 0,0,53324 0,0,53763 0,53768 0,0,5208 9,38053 0,52011 0,53745 0,53745 0,555099 0,414406 9,286468 0,53324 1,0,25311 0,53745 0,57113 0,55209 9,286468 0,53288 9,0,22022 0,71579 0,900689 0,772403 0,111352 1,0,5306 0,532648 0,53262 0,576299 1,272432 1,0,52069 9,24649 1,111362 1,0,23060 1,270924 0,270924 0,270924 0,27092 0,270924 0,27092 0,270924 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0,27092 0
                                                           S00 mt. Total Drug To
Corrected Neg Contr P1
```

Total Drug Avg (P1, P2 P3) in milligrams 0.345308557 0.502310659 0.502310659 0.627808286 0.616254772 1.11136266 1.6011151 2.247640064 2.250622085 3.34025668 3.34025682 3.34025683 4.14052688 4.181735986 4.251867048 4.251867048 4.251867048 9.17344786 9.286467752 9.286467752 9.286467752 9.286467752 9.286467752 9.13284786 9.1724786 9.273957806 9.273957806 9.273957806 9.273957806 9.273957806 8.77767824 8.740204943 8.043248945 9.455997589 9.418324292

500 mt. Corrected Day

1 以 以 大學

And the state of

```
P2C P3C Avg (P1C; P2C; P3C)

0.43621861 0.474485 0.474485 0.411105346

0.34253628 0.531005 0.361475 0.411706349

0.323811889 0.556678 0.471885 0.411706349

0.713371690 0.556678 0.77289 1.152614527

1.11464123 1.256544 0.77289 1.152614527

2.39593333 2.70623 0.77289 1.152614527

2.39593333 2.70623 0.77289 1.152614527

2.39593333 2.70623 0.77289 1.152614527

2.39593333 2.70623 0.77289 1.152614527

3.35570541 0.77289 1.152614527

3.3557054 0.77289 1.77289 1.77289

4.00568355 3.7769 0.77289 3.79551426

4.72295624 3.77295 1.75239 1.772951426

4.72295624 3.7729566 3.75279 3.772954457

4.772958142 3.80582 3.77593 3.772954457

4.772981872 3.80726 3.878172

4.772958143 4.47654 4.081122

4.772958143 4.47654 4.081122

4.772958152 4.77584 4.081122

4.772958152 4.77584 4.081122
                                                                       P1C
Total Drug
500 mL Total Ong Total Ong Total Ong Total Ong Total Ong Total Ong Corrected Neg Corri Pt P2 P3 Pos Corring O157896 0.327221 0.357896 0.357896 0.357896 0.357396 0.353948 0.25339 0.0357896 0.34539 0.0478916 0.43243 0.650466 0.670916 9.39488 0.52147 0.45208 0.627609 0.695222 0.652623 9.380651 0.722072 9 0.33527 0.52509 0.695222 0.652623 9.380651 0.722072 9 0.33527 0.52509 0.52450 0.52450 0.52509 0.524141 0.52972 11 0.37573 1.02525 0.52429 0.69452 9.524141 1.732972 16 0.37573 1.32597 1.808318 1.657625 9.224141 1.732972 16 0.37573 1.31525 2.84434 3.00545 9.24679 3.064095 21 0.37573 3.31525 2.84434 3.0027 9.24679 3.064095 22 0.375103 3.95525 2.99507 2.90084 9.271121 2.35052 2.9079113 3.97533 3.4560 2.24679 3.027 9.24679 3.750505 22 0.056648 3.97433 3.46943 3.77613 9.24679 3.756166 3.70 0.66648 4.068718 3.756166 3.70 0.66648 4.068718 3.756166 3.70 0.66648 4.068718 3.756166 3.70 0.66648 4.068718 3.756166 3.70 0.66548 4.068718 3.76616 3.99648 3.97433 3.90649 3.97633 9.24879 9.24879 4.162899 4.018936 4.24879 4.162899 4.018936 4.24879 4.162899 4.018936 4.200577 4.005399 4.005399 9.24879 9.24879 4.162899 4.018936 4.200577 4.005399 4.005399 9.24879 9.24879 4.162899 4.018936 4.200577 4.005399 4.005399 9.24879 9.24879 4.162899 4.018936 4.200577 4.005399 4.005399 9.24879 4.162899
```